Results 141 to 150 of about 1,096,024 (260)

"A 10% rate ... no food exemptions ... a sure winner...", "Do you think it's something in the water?", GST on agenda again, 1998 [picture] /

open access: yes, 1998
Condition: Good.; Published in: Sydney Morning Herald 1998.; Part of the Moir collection of cartoons and drawings.; Inscriptions: "1998 GST on agenda again." -- in ink on reverse.; Also available in an electronic version via the Internet at: http://nla ...
Moir, Alan (Alan Charles), 1945-
core  

Efficacy and Safety of Nanoencapsulated Sirolimus Plus Pegadricase: Results From the Randomized, Placebo‐Controlled Phase 3 Trials

open access: yesArthritis &Rheumatology, EarlyView.
Objective DISSOLVE I and II examined the efficacy and safety of nanoencapsulated sirolimus (NAS) plus pegadricase (NASP) in patients with uncontrolled gout (UG). Methods In these double‐blind, placebo‐controlled Phase 3 trials of NASP, patients were randomized 1:1:1 to infusions of high‐dose (HD) or low‐dose (LD) NAS plus pegadricase (HD NASP, LD NASP,
Herbert S. B. Baraf   +15 more
wiley   +1 more source

Mitigating artificial light at night: effectiveness of policies and implications for plant phenology. [PDF]

open access: yesPNAS Nexus
Geist B   +7 more
europepmc   +1 more source

"Oi! Leave some for me, mate!", November 2003 [picture] /

open access: yes, 2003
Condition: Good.; Published in: Sydney Morning Herald 2003.; Part of the Moir collection of cartoons and drawings.; Inscription: "Nov. 2003." -- in ink on reverse.; Also available in an electronic version via the Internet at: http://nla.gov.au/nla.pic ...
Moir, Alan (Alan Charles), 1945-
core  

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week (W), double‐blind, placebo‐controlled, phase 3 POETYK PsA‐2 study
Philip J. Mease   +20 more
wiley   +1 more source

"You're all very quiet this morning" [John Howard enters the Party room where Alexander Downer, Peter Costello, Peter Reith, David Kemp and Amanda Vanstone are reading newspapers about the resignation of New Zealand Prime Minister Jim Bolger] [picture] /

open access: yes, 1997
Title devised by cataloguer.; Inscriptions: "June 2000; Howard popularity down"--in ink on verso.; Published in 1997? (the year of Jim Bolger's resignation).; Published in the Sydney Morning Herald.; Part of the Moir collection of cartoons and drawings.;
Moir, Alan (Alan Charles), 1945-
core  

Complement Activation Linked to Type II Interferon Signaling in Still Disease

open access: yesArthritis &Rheumatology, EarlyView.
Objective Still disease (SD) is an autoinflammatory syndrome characterized by innate immune dysregulation. Although complement can drive inflammation, its involvement in SD remains to be defined. Thus, we aimed to assess complement activation in SD. Methods Complement was assessed using transcriptomic, proteomic, and in vitro approaches. RNA sequencing
Freya M. C. H. Huijsmans   +115 more
wiley   +1 more source

Home - About - Disclaimer - Privacy